期刊
BIOESSAYS
卷 38, 期 5, 页码 446-454出版社
WILEY
DOI: 10.1002/bies.201500162
关键词
cancer; epigenetic modifications; Polycomb proteins; PRC2
资金
- la Caixa Foundation
- Spanish Ministerio de Educacion y Ciencia [SAF2013-48926-P]
- AGAUR
- La Marato TV3
- Fundacion Vencer El Cancer (VEC)
- Spanish Ministry of Economy and Competitiveness Centro de Excelencia Severo Ochoa [SEV-2012-0208]
- European Commission [277899]
- ICREA Funding Source: Custom
The Polycomb group of proteins (PcGs) are transcriptional repressor complexes that regulate important biological processes and play critical roles in cancer. Mutating or deleting EZH2 can have both oncogenic and tumor suppressive functions by increasing or decreasing H3K27me3. In contrast, mutations of SUZ12 and EED are reported to have tumor suppressive functions. EZH2 is overexpressed in many cancers, including prostate cancer, which can lead to silencing of tumor suppressors, genes regulating epithelial to mesenchymal transition (EMT), and interferon signaling. In some cases, EZH2 overexpression also leads to its use of non-histone substrates. Lastly, PRC2 associated factors can influence the progression of cancer through progressive mutations or by specific binding to certain target genes. Here, we discuss which mutations and deletions of the PRC2 complex have been detected in different cancers, with a specific focus on the overexpression of EZH2 in prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据